Welcome to our dedicated page for Zynex SEC filings (Ticker: ZYXI), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Struggling to spot FDA risk disclosures or recurring supply revenue inside Zynex’s 200-page reports? Medical-device filings can bury the details that move the stock—whether it’s reimbursement trends, electrode reorder margins, or how new cardiac monitors could reshape growth.
Our platform solves this by linking each disclosure to the exact SEC form you need. The moment a Zynex quarterly earnings report 10-Q filing or Zynex 8-K material events explained hits EDGAR, AI generates a concise summary, flags segment revenue shifts, and highlights anything the market may miss. Real-time alerts surface Zynex Form 4 insider transactions real-time, so you never wait to learn when executives buy or sell.
Here’s what you can explore today:
- Annual perspective: A Zynex annual report 10-K simplified breakdown of FDA pathways, supply-chain dependencies, and reimbursement sensitivity.
- Quarter-to-quarter pulse: Instant AI commentary on margins, unit volume, and cash flow inside each 10-Q.
- Governance clarity: The Zynex proxy statement executive compensation decoded—see how pay aligns with R&D milestones.
- Insider visibility: Track every Zynex executive stock transactions Form 4 alongside trend analytics.
Need quick answers? Ask, “Zynex SEC filings explained simply,” “understanding Zynex SEC documents with AI,” or dive into our Zynex earnings report filing analysis to compare segment growth. Whether you’re researching Zynex insider trading Form 4 transactions or validating forecasts, Stock Titan delivers complete coverage—AI-powered summaries, expert annotations, and real-time updates across every filing type.
Zynex, Inc. has entered into a senior secured debtor-in-possession credit agreement for a $22.3 million term loan to fund its Chapter 11 restructuring. The DIP facility is available in three draws of $10.15 million, $5.0 million and $7.15 million, and carries 10.0% annual interest paid in kind plus substantial fees, including an upfront fee of $669,000, an exit fee of $669,000 and a $5,000,000 backstop fee, along with a minimum 2.00x return on invested capital. The loan matures on the earliest of 105 days after the Chapter 11 filing, an event of default, or completion of a sale of substantially all assets, and is secured by first-priority liens on nearly all of the company’s assets.
Zynex also received notice that Nasdaq will delist its common stock due to the Chapter 11 cases, with trading to be suspended on December 24, 2025; the company does not intend to appeal. Zynex cautions that trading in its securities is highly speculative and states that equity holders are expected to experience a significant loss on their investment if the contemplated restructuring transactions are implemented.
Zynex, Inc. has filed voluntary Chapter 11 cases in the U.S. Bankruptcy Court for the Southern District of Texas, beginning a court-supervised reorganization of the company and certain subsidiaries. The company entered a restructuring support agreement with holders of approximately 80% of its 5.00% Convertible Senior Notes due 2026 and arranged a proposed
The restructuring framework contemplates a competitive sale process under a chapter 11 plan, with the DIP lenders acting as stalking-horse bidder and plan sponsor, and milestones targeting interim and final DIP approval, a bid deadline 75 days after the petition date, an auction (if needed), plan confirmation by 95 days, and emergence by 105 days. The Chapter 11 filing triggered an event of default on approximately
Zynex, Inc. (ZYXI) director Paul Aronzon filed an initial Form 3 reporting his beneficial ownership status as of 11/11/2025. The filing states that he is a director of Zynex and that he does not beneficially own any Zynex securities. This is a baseline disclosure required when an insider first becomes subject to reporting rules.
Zynex, Inc. (ZYXI) filed a current report to announce that it released a press release with its financial results for the third quarter of 2025. The press release, dated November 17, 2025, is included as Exhibit 99.1 and is incorporated by reference into the report. The company states that the information in this item, including the press release, is being furnished rather than filed under securities law, which affects how related legal liabilities apply.
Zynex, Inc. filed a Form 12b-25 to notify a delay in its Form 10-Q for the quarter ended September 30, 2025. The company needs additional time to finalize the Q3 financial statements and related disclosures.
Management anticipates the upcoming Form 10-Q will disclose substantial doubt about the company’s ability to continue as a going concern, citing that current cash resources are not sufficient to support planned operations for at least 12 months from the expected issuance date of the Q3 financial statements.
Zynex expects to file the Form 10-Q within the five-day grace period allowed under Rule 12b-25.
Zynex, Inc. reported leadership changes tied to the resignation of Chief Commercial Officer Anna Lucsok. Her resignation was effective October 10, 2025, with separation terms finalized on October 27, 2025.
Under her employment agreement, Ms. Lucsok is entitled to severance, conditioned on her execution, non-revocation, and compliance with a Separation Agreement dated October 27, 2025. The Compensation Committee also approved the accelerated vesting of 60,746 unvested restricted shares previously issued to her, effective as of the Separation Date and subject to the same conditions.
Zynex, Inc. (ZYXI) reported a new director appointment disclosure. A Form 3 initial statement of beneficial ownership was filed indicating the reporting person is a Director and no securities are beneficially owned. The event date is 10/07/2025, and the filing was made by a single reporting person. This is a routine governance filing that establishes the insider’s baseline holdings at zero.
Zynex, Inc. appointed Bret W. Wise to its Board, expanding the board from five to six members effective October 7, 2025. Wise will serve until the 2026 annual meeting and was named Chair of the Audit Committee, and a member of the Compensation and Nominating and Governance Committees.
Director compensation: Wise will receive annual cash retainers of $40,000 (Board), $20,000 (Audit Chair), $7,500 (Compensation Committee), and $5,000 (Nominating and Governance), paid quarterly in arrears and pro‑rated as applicable. He will also receive an initial grant of 20,000 restricted shares and an annual grant of 10,000 restricted shares upon re‑election, vesting quarterly over three years, beginning one quarter after grant, subject to continued service.
Additional updates: Chair Thomas Sandgaard will receive annual retainers of $150,000 (Board Chair) and $250,000 (Technology Committee Chair), paid quarterly in arrears. Chief Commercial Officer Anna Lucsok resigned effective October 10, 2025.
FAQ
What is the current stock price of Zynex (ZYXI)?
What is the market cap of Zynex (ZYXI)?
